)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Aclaris Therapeutics (ACRS) investor relations material
Aclaris Therapeutics R&D Day 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.R&D Day 2025 summary14 Oct, 2025
Pipeline overview and program updates
Four clinical programs expected in 2026, including ATI-2138, Bosakitug (ATI-045), ATI-052, and next-generation ITK-selective inhibitors, with additional multispecific antibodies in preclinical development and INDs planned for 2026 and 2027.
Portfolio includes both oral small molecules and biologics, targeting TH1, TH2, and TH17 pathways, with lead assets positioned as potential game changers in multiple indications.
Cash runway extends into the second half of 2028, supporting execution across the portfolio and all planned preclinical and clinical development.
Clinical trial data and development milestones
ATI-2138 (ITK/JAK3 inhibitor) completed Phase 2a in atopic dermatitis with favorable safety and efficacy, advancing to Phase 2 in lichen planus in 1H 2026.
Bosakitug (ATI-045) is in a two-arm, placebo-controlled Phase 2 trial for moderate-to-severe AD, with results expected in 2H 2026; high potency and long half-life demonstrated in Phase 2a.
ATI-052 (bispecific anti-TSLP/IL-4Ra) is in Phase 1a/1b SAD/MAD studies, with top-line results expected in 1Q 2026 and POC trials in asthma and AD planned for 2026.
Centralized photographic review and strict eligibility criteria implemented in dermatology trials to ensure high-quality data and reduce placebo response.
Multiple clinical readouts anticipated across the portfolio in 2026, including ATI-052, Bosakitug, and ATI-2138.
R&D strategy and innovation priorities
Focus on developing best-in-class oral kinase inhibitors and multi-specific antibodies to address unmet needs in immunology and inflammation.
Proprietary KINect platform enables rapid development of kinase inhibitors targeting previously undruggable kinome regions.
Emphasis on high potency, specificity, and innovative mechanisms, including dual and trispecific antibody formats, covalent inhibitors, molecular glues, and protein degraders.
State-of-the-art R&D capabilities in St. Louis support rapid and deep profiling of internal and in-licensed molecules.
How will ATI-052's 1b studies differentiate it?
What is the safety advantage of ITK selectivity?
Aclaris's lead indication selection process?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aclaris Therapeutics earnings date
Q3 20255 Nov, 2025
Next Aclaris Therapeutics earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Aclaris Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily engaged in the development of novel drug candidates for immuno-inflammatory diseases. Leveraging its core expertise in drug discovery, development, and kinase inhibition, Aclaris focuses on creating small molecule therapies for people affected by underserved immuno-inflammatory conditions. Its proprietary KINect® technology platform enables the development of clinical candidates targeting challenging kinases with novel approaches. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a full-service drug discovery and early development contract research organization. This subsidiary offers research partnership services across therapeutic areas and gene families, with expertise in a range of scientific disciplines including cell and molecular biology, biochemistry, enzymology, and immunology. he company is headquartered in Wayne, Pennsylvania, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage